Harvard Bioscience (HBIO) Non-Current Deferred Tax Liability (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Non-Current Deferred Tax Liability data on file, last reported at $313000.0 in Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $313000.0, down 56.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $313000.0 (down 56.35% YoY), and the FY2025 annual result was $317000.0, down 55.35% from the prior year.
• Non-Current Deferred Tax Liability retreated to $313000.0 in Q1 2026 per HBIO's latest filing, from $317000.0 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $2.4 million in Q2 2022 and troughed at $313000.0 in Q1 2026.
• A 5-year average of $826882.4 and a median of $717000.0 in 2025 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability jumped 54.39% in 2022, then tumbled 72.52% in 2023.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $590000.0 in 2022, then jumped by 31.53% to $776000.0 in 2023, then retreated by 8.51% to $710000.0 in 2024, then plunged by 55.35% to $317000.0 in 2025, then retreated by 1.26% to $313000.0 in 2026.
• Business Quant data shows HBIO's Non-Current Deferred Tax Liability at $313000.0 in Q1 2026, $317000.0 in Q4 2025, and $733000.0 in Q3 2025.